Investigations Target uniQure N.V. Over Huntington’s Trial Disclosures and BLA Timeline

Investigations Mount over uniQure’s Huntington’s Disease Trial Statements

On Feb. 13, 2026, three investor‑rights law firms announce class actions against uniQure N.V., accusing the gene‑therapy specialist of making false or misleading statements about the regulatory status and design of its Pivotal Study for a Huntington’s disease treatment. The firms — The Schall Law Firm, DJS Law Group and Rosen Law Firm — say public disclosures during a September‑24 to Oct.‑31, 2025 class period mischaracterize the study’s comparison to the ENROLL‑HD external dataset and understate the likelihood that additional data or studies will be required before a Biologics License Application (BLA) can proceed.

Shareholders Allege Misleading Claims on Pivotal Study and BLA Timing

The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b‑5, alleging uniQure represented that the Pivotal Study and its external control comparison had secured the regulatory footing needed for full FDA approval when, plaintiffs contend, the evidence did not support that position. Law firms say uniQure downplayed the chance it would need to delay its BLA timeline to supplement trial data, exposing investors to losses when subsequent disclosures alter prospects for approval and commercialization.

Each firm notifies eligible purchasers of ordinary shares during the specified class period that they may seek to participate in litigation or move for lead‑plaintiff appointment, with April 13, 2026, cited as the deadline to apply for lead status. The notices emphasise that the class has not been certified and that plaintiffs are not yet represented by counsel, while soliciting worldwide claimants and offering contingency fee arrangements and free initial consultations to assess potential recovery and preserve claims.

The litigation centres on technical regulatory issues that are material to a gene‑therapy developer’s pathway to market: whether an external historical control like ENROLL‑HD provides adequate comparability, and whether the Pivotal Study’s design and data are sufficiently robust to support a BLA. The outcomes of these suits will depend on court findings about the adequacy of uniQure’s disclosures and investors’ proof of losses, and firms point to their track records in securities class actions as they pursue potential recoveries.

Investor Steps and Broader Industry Implications

Potential claimants are urged to preserve transaction records and submit claims promptly; law firms provide procedural guidance and encourage shareholders considering lead‑plaintiff motions to act before the April deadline. Firms note that participation choices affect representation and recovery routes.

The complaints highlight wider scrutiny of regulatory strategies in the biotech sector, where reliance on external control datasets and the timing of supplemental studies can materially affect approval prospects and company planning for rare neurodegenerative disease therapies.